Physician profile
Stanley E Clark
NPI 1629016951
$6,674.66
in general payments reported to CMS, 2019-2025
22 companies · $933 in 2025
The $933 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $753 · 2021: $66.69 · 2022: $248 · 2023: $599 · 2024: $3,662 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,094 · Travel and Lodging: $2,003 · Entertainment: $95.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,093.85 |
| Travel and Lodging | $2,003.42 |
| Entertainment | $95.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,886.77 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Edwards Lifesciences Corporation | $1,591.18 | 2019-2025 | Evoque, Pascal, Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $833.39 | 2019-2025 | Watchman Access System, Watchman Flx, Watchman |
| Novartis Pharmaceuticals Corporation | $579.32 | 2019-2025 | |
| Cardiva Medical, INC. | $470.94 | 2024-2025 | Savvywire, Optowire, Cardiva Vascade 6/7f Vcs |
| E.R. Squibb & Sons, L.L.C. | $315.35 | 2020-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $272.67 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Onyx Frontier |
| Amgen INC. | $152.94 | 2022-2025 | Repatha, Repatha |
| Opsens INC. | $132.67 | 2022-2023 | Optowire |
| Sanofi-Aventis U.S. LLC | $80.12 | 2019-2024 | |
| Pfizer INC. | $61.03 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.52 | 2024-2025 | Jardiance |
| Chiesi USA, INC. | $38.85 | 2019-2022 | |
| Heartflow, INC. | $37.99 | 2025 | |
| Merck Sharp & Dohme LLC | $37.07 | 2023-2024 | Verquvo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $28.01 | 2024 | Self-Cath |
| Alnylam Pharmaceuticals INC. | $23.71 | 2025 | Amvuttra |
| Kestra Medical Technology Services, INC. | $21.43 | 2025 | Assure Wcd |
| Scpharmaceuticals INC. | $20.46 | 2025 | |
| Adagio Medical, INC. | $18.26 | 2022 | |
| Surmodics, INC. | $17.79 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.19 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.